- ►asnjournals.org M Morena, N Terrier, I Jaussent, H Leray- … - Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol Expression of bone proteins resulting from transdifferentiation of vascular
smooth muscle cells into osteoblasts suggests that vascular calcifications are a
bioactive process. Regulating molecules such as osteoprotegerin (OPG) and ... Cited by 61 - Related articles - BL Direct - All 5 versions
G Zauli, P Secchiero - Cytokine and Growth Factor Reviews, 2006 - Elsevier TRAIL is a member of the tumor necrosis factor superfamily that interacts with
an unusually complex receptor system, comprising transmembrane (TRAIL-R1, -R2,
-R3 and -R4) and soluble (osteoprotegerin) receptors. TRAIL has received ... Cited by 54 - Related articles - All 15 versions
- ►onlinejacc.org DV Anand, A Lahiri, E Lim, D Hopkins, R … - Journal of the American College of Cardiology, 2006 - Elsevier This study sought to prospectively evaluate the relationship between plasma
osteoprotegerin (OPG), inflammatory biomarkers (high-sensitivity C-reactive
protein [hs-CRP], interleukin-6 [IL-6], coronary artery calcification ... Cited by 53 - Related articles - BL Direct - All 7 versions
M Abedin, T Omland, T Ueland, A Khera, P … - The American journal of cardiology, 2007 - Elsevier Circulating osteoprotegerin (OPG) has been shown to be elevated in patients with
vascular disease. The role of OPG as a biomarker for atherosclerosis in a large,
unselected population is not well known. Plasma OPG levels were measured in ... Cited by 32 - Related articles - All 13 versions
- ►shouxi.net G Xiang, L Xu, L Zhao, L Yue, J Hou - Diabetes, 2006 - Am Diabetes Assoc Osteoprotegerin is a recently identified inhibitor of bone resorption. Recent
studies indicate that osteoprotegerin also acts as an important regulatory
molecule in the vasculature. The purpose of this study was to investigate ... Cited by 25 - Related articles - BL Direct - All 6 versions
- ►amjpathol.org P Secchiero, F Corallini, A Pandolfi, A … - American Journal of Pathology, 2006 - ASIP Serum osteoprotegerin (OPG) is significantly increased in diabetic patients,
prompting expanded investigation of the correlation between OPG
production/release and glycemic levels. Serum levels of OPG, but not of its ... Cited by 24 - Related articles - BL Direct - All 9 versions
MH Gannagé-Yared, F Fares, M Semaan, S … - CLINICAL ENDOCRINOLOGY-OXFORD-, 2006 - pt.wkhealth.com This work was supported by a grant from the 'Conseil de Recherche de
l'Université Saint-Joseph' (FM 99). ... Relation between serum OPG levels and
cardiovascular risk f... ... Correlations between serum OPG levels, lipid ... Cited by 17 - Related articles - BL Direct - All 6 versions
G Xiang, H Sun, L Zhao - Diabetes research and clinical practice, 2007 - Elsevier Plasma OPG level in patients before treatment was 3.09 ± 0.70 ng/L, which was
significantly higher than that in control (2.07 ± 0.75 ng/L) (p < 0.001). After
6 months treatment, OPG levels decreased markedly (2.58 ± 0.59 ng/L) (p < ... Cited by 14 - Related articles - BL Direct - All 4 versions
- Free from Publisher A Avignon, A Sultan, C Piot, D Mariano- … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—A total of 92 patients were diagnosed with SMI. Of the six novel
markers, osteoprotegerin was the only one associated with SMI; the relative risk
(RR) of SMI in patients with osteoprotegerin values above the 75th ... Cited by 16 - Related articles - BL Direct - All 5 versions
